C WorldWide Group Holding A S Boosts Holdings in Insulet Co. (NASDAQ:PODD)

C WorldWide Group Holding A S grew its position in Insulet Co. (NASDAQ:PODD) by 42.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 167,908 shares of the medical instruments supplier’s stock after purchasing an additional 50,000 shares during the quarter. Insulet comprises approximately 0.5% of C WorldWide Group Holding A S’s investment portfolio, making the stock its 23rd biggest holding. C WorldWide Group Holding A S’s holdings in Insulet were worth $36,433,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in PODD. Consolidated Portfolio Review Corp grew its position in Insulet by 1.6% during the 4th quarter. Consolidated Portfolio Review Corp now owns 3,713 shares of the medical instruments supplier’s stock worth $806,000 after purchasing an additional 57 shares during the last quarter. Linden Thomas Advisory Services LLC grew its holdings in shares of Insulet by 1.3% during the fourth quarter. Linden Thomas Advisory Services LLC now owns 5,817 shares of the medical instruments supplier’s stock valued at $1,262,000 after buying an additional 73 shares during the last quarter. Lindbrook Capital LLC increased its position in shares of Insulet by 64.1% in the 4th quarter. Lindbrook Capital LLC now owns 192 shares of the medical instruments supplier’s stock valued at $42,000 after acquiring an additional 75 shares during the period. New York Life Investment Management LLC raised its stake in Insulet by 0.8% in the 3rd quarter. New York Life Investment Management LLC now owns 10,035 shares of the medical instruments supplier’s stock worth $1,600,000 after acquiring an additional 82 shares during the last quarter. Finally, Avior Wealth Management LLC lifted its position in Insulet by 3.6% during the 4th quarter. Avior Wealth Management LLC now owns 2,645 shares of the medical instruments supplier’s stock worth $574,000 after acquiring an additional 91 shares during the period.

Analyst Ratings Changes

PODD has been the subject of several recent research reports. Piper Sandler reduced their target price on shares of Insulet from $250.00 to $230.00 and set an “overweight” rating for the company in a report on Friday, February 23rd. Barclays cut their price objective on shares of Insulet from $214.00 to $213.00 and set an “equal weight” rating for the company in a report on Monday, February 26th. JPMorgan Chase & Co. increased their target price on shares of Insulet from $190.00 to $225.00 and gave the stock an “overweight” rating in a research note on Friday, February 23rd. Finally, Stifel Nicolaus lifted their price target on Insulet from $163.00 to $208.00 and gave the company a “hold” rating in a research note on Monday, February 5th. Four research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $243.21.

Insulet Stock Performance

PODD stock traded up $2.02 during trading on Friday, hitting $166.19. The company had a trading volume of 636,152 shares, compared to its average volume of 670,432. Insulet Co. has a 1-year low of $125.82 and a 1-year high of $335.91. The company has a quick ratio of 2.62, a current ratio of 3.51 and a debt-to-equity ratio of 1.86. The firm has a 50-day moving average price of $171.51 and a 200-day moving average price of $179.39. The firm has a market cap of $11.64 billion, a PE ratio of 57.11, a price-to-earnings-growth ratio of 2.96 and a beta of 0.98.

Insulet (NASDAQ:PODD) last posted its earnings results on Thursday, February 22nd. The medical instruments supplier reported $1.40 EPS for the quarter, topping analysts’ consensus estimates of $0.67 by $0.73. Insulet had a return on equity of 32.19% and a net margin of 12.16%. The company had revenue of $509.80 million for the quarter, compared to the consensus estimate of $461.26 million. During the same period in the previous year, the business earned $0.55 earnings per share. Insulet’s quarterly revenue was up 37.9% compared to the same quarter last year. On average, analysts expect that Insulet Co. will post 3.08 earnings per share for the current year.

Insider Activity at Insulet

In other news, Director Shacey Petrovic sold 11,609 shares of the company’s stock in a transaction dated Wednesday, February 28th. The shares were sold at an average price of $162.92, for a total value of $1,891,338.28. Following the sale, the director now owns 2,567 shares in the company, valued at approximately $418,215.64. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. 0.90% of the stock is owned by insiders.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.